$3.93 Billion in Sales Expected for Becton Dickinson and Co (NYSE:BDX) This Quarter

Wall Street brokerages expect that Becton Dickinson and Co (NYSE:BDX) will report $3.93 billion in sales for the current quarter, Zacks reports. Eight analysts have issued estimates for Becton Dickinson and’s earnings. The lowest sales estimate is $3.87 billion and the highest is $3.97 billion. Becton Dickinson and reported sales of $4.35 billion in the same quarter last year, which indicates a negative year over year growth rate of 9.7%. The business is expected to report its next earnings report on Tuesday, August 4th.

According to Zacks, analysts expect that Becton Dickinson and will report full year sales of $16.92 billion for the current year, with estimates ranging from $16.69 billion to $17.11 billion. For the next financial year, analysts forecast that the business will post sales of $18.31 billion, with estimates ranging from $17.93 billion to $18.72 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Becton Dickinson and.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.32 by $0.23. Becton Dickinson and had a net margin of 6.10% and a return on equity of 15.75%. The firm had revenue of $4.25 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the previous year, the company earned $2.59 earnings per share. The business’s revenue was up 1.4% compared to the same quarter last year.

BDX has been the subject of several recent research reports. Goldman Sachs Group initiated coverage on Becton Dickinson and in a report on Sunday, May 31st. They set a “buy” rating and a $278.00 price objective for the company. Piper Sandler boosted their price objective on Becton Dickinson and from $286.00 to $296.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. KeyCorp reaffirmed a “hold” rating on shares of Becton Dickinson and in a research note on Tuesday, May 12th. Zacks Investment Research cut Becton Dickinson and from a “hold” rating to a “sell” rating and set a $245.00 price target for the company. in a research note on Wednesday, May 27th. Finally, Raymond James lowered their price target on Becton Dickinson and from $290.00 to $265.00 and set an “outperform” rating for the company in a research note on Thursday, June 25th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $272.00.

In other Becton Dickinson and news, EVP Patrick Kaltenbach sold 1,049 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $243.20, for a total value of $255,116.80. Following the transaction, the executive vice president now directly owns 12,661 shares in the company, valued at approximately $3,079,155.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.12% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wealth Quarterback LLC acquired a new stake in shares of Becton Dickinson and in the 4th quarter worth about $7,588,711,000. State Street Corp boosted its stake in Becton Dickinson and by 0.3% during the first quarter. State Street Corp now owns 11,490,473 shares of the medical instruments supplier’s stock worth $2,640,166,000 after buying an additional 39,890 shares in the last quarter. Wellington Management Group LLP boosted its stake in Becton Dickinson and by 225.4% during the first quarter. Wellington Management Group LLP now owns 8,473,220 shares of the medical instruments supplier’s stock worth $1,946,892,000 after buying an additional 5,869,236 shares in the last quarter. Morgan Stanley boosted its stake in Becton Dickinson and by 1.0% during the first quarter. Morgan Stanley now owns 5,901,391 shares of the medical instruments supplier’s stock worth $1,355,965,000 after buying an additional 55,633 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Becton Dickinson and by 27.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 4,086,572 shares of the medical instruments supplier’s stock worth $938,970,000 after buying an additional 885,564 shares in the last quarter. Institutional investors and hedge funds own 85.78% of the company’s stock.

NYSE BDX traded up $2.80 on Friday, hitting $235.77. 45,682 shares of the company were exchanged, compared to its average volume of 2,035,168. The firm has a 50 day moving average of $242.58 and a two-hundred day moving average of $252.53. The company has a market cap of $63.16 billion, a P/E ratio of 70.15, a P/E/G ratio of 3.09 and a beta of 0.93. The company has a current ratio of 0.98, a quick ratio of 0.66 and a debt-to-equity ratio of 0.80. Becton Dickinson and has a 1-year low of $197.75 and a 1-year high of $286.72.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, June 8th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.34%. Becton Dickinson and’s payout ratio is 27.05%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Yield Curve

Get a free copy of the Zacks research report on Becton Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.